3.12
-0.01(-0.32%)
Currency In HKD
Sector
Healthcare
Industry
Biotechnology
Employees
294
First IPO Date
April 29, 2021
| Name | Title | Pay | Year Born |
| Dr. Xiaoyi Li Ph.D. | Chief Executive Officer & Executive Chairman of the Board | 11.92M | 1963 |
| Mr. Xiangrong Dai | Chief Operating Officer & Executive Director | 2.11M | 1980 |
| Mr. Jiang Feng | Senior Vice President of Sales & Marketing | 0 | 1976 |
| Ms. Yang Lei | Group General Counsel | 0 | 1981 |
| Ms. Carol Liu | Group Head of Regulatory Affairs | 0 | 1984 |
| Dr. Lit Fui Lau | President & Chief Scientific Officer | 0 | 1963 |
| Dr. Mauro Bove Ph.D. | Senior Vice President of Corporate Development | 0 | 1955 |
| Mr. Guohui Zhang | Senior Vice President of Manufacturing & Logistics | 0 | 1974 |
| Ms. Suk Yan Yau CPA | Vice President of Financial Dept. & Company Secretary | 0 | 1982 |
Zhaoke Ophthalmology Limited, an ophthalmic pharmaceutical company, engages in the research, development, and commercialization of therapies that address unmet medical needs in the People's Republic of China. It is developing various drugs that cover ophthalmic indications affecting the anterior and posterior segments, including dry eye diseases, wet age-related macular degeneration, diabetic macular edema, myopia, and glaucoma. The company was formerly known as China Ophthalmology Focus Limited. Zhaoke Ophthalmology Limited was incorporated in 2017 and is headquartered in Guangzhou, the People's Republic of China.
